DoseGear research brief
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22. 7% weight loss with CagriSema combination.
DG Peptide Protocols
Extensively StudiedWeight LossMetabolic
Cagrilintide
AM833
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Research overview
Mechanism of action
Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Long-acting lipidated amylin analog.
What it is researched for
Weight-management and metabolic-disease trials, including combination research with semaglutide.
Research observation window
Cited CagriSema combination studies ran 32 and 68 weeks; these do not establish a cagrilintide-alone response window.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Weight Loss (Monotherapy) | 2.4mg | Once weekly | SubQ |
| Weight Loss (CagriSema) | 2.4mg + semaglutide 2.4mg | Once weekly | SubQ |
| Type 2 Diabetes Management | 2.4mg weekly | Once weekly | SubQ with metformin |
| Dose Escalation Protocol | 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg | Weekly increases over 16 weeks | SubQ |
Reference cycle
Continuous long-term therapy
Reference storage
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days
Safety context
Reported side effects
- Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
- Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
- Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Contraindications & cautions
- Not recommended in pregnancy or breastfeeding
- Not yet commercially available (FDA approval expected Q1 2026)
Scientific references
- 01
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Scientific citationCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine (2025). - 02
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Scientific citationCagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine (2025). - 03
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Scientific citationEfficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet (2023).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.